コンテンツへ移動

ニュース – 診療報酬コンシェルジュ

医科
歯科
製薬・バイオ

要点

8月 24, 2026

記事のコンテンツが提供されていません。

元記事：Cyberbullying may fuel teen mental health problems through loneliness, study finds

カテゴリー

医科

関連記事

6月 1, 2026 医科

ホルモン感受性前立腺がんにおけるタラゾパリブとエンザルタミドの併用療法が画像診断上の無増悪生存期間を大幅に改善
4月 7, 2026 医科

皮膚付属器腫瘍：黒人患者は治療までの待ち時間が長く、予後が不良
1月 19, 2026 医科

RAAC製病院、2030年の再建期限に間に合わず
11月 1, 2025 医科

— outputs: – name: タイトル desc: 記事のタイトルを日本語に翻訳 input: article: | Until recently, clinicians could only counsel lifestyle changes for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH). Now, with the FDA’s approvals of semaglutide and resmetirom, treatment choices have expanded for patients whose disease has advanced to MASH.An Increasingly Common DiseaseMASLD has emerged as a leading cause of chronic liver disease, driven by the increased prevalence of metabolic disorders such as diabetes and obesity.The Power of GLP-1sThe ESSENCE study, published in The New England Journal of Medicine, found that 2.4 mg of semaglutide once a week improved liver histology in patients with MASH and moderate or advanced fibrosis. GLP-1s, like semaglutide, may be appropriate for patients with coexisting obesity or diabetes, though gastrointestinal-related adverse effects and access issues could limit its use.Resmetirom’s Targeted ApproachResmetirom acts directly on liver cells to improve lipid metabolism and may help reduce fibrosis. The MAESTRO-NASH trial, published in The New England Journal of Medicine, included adults with biopsy confirmed MASH and F2-F3 fibrosis and found resmetirom 80 mg and 100 mg produced MASH resolution without a worsening of fibrosis. Resmetirom is currently recommended only for patients with F2-F3 fibrosis. Gastrointestinal-related adverse effects are also common with this drug.Matching Drug to PatientThe choice of drug should be individualized on the basis of comorbidities. For example, GLP-1s, like semaglutide, may be beneficial for patients with coexisting diabetes or obesity, whereas resmetirom may be better suited for those with advanced liver disease, low BMI, or an inability
8月 18, 2026 医科

性的暴行サバイバー、感染症予防薬を服用せず – Medscape
9月 19, 2025 医科

2型糖尿病女性における経皮ホルモン補充療法は虚血性心疾患のリスク低下と関連、経口ホルモン補充療法は心血管系イベント増加と関連

Home
医科
要点

© 2026 ニュース – 診療報酬コンシェルジュ

yStandard Theme by yosiakatsuki Powered by WordPress